γ-Linolenic Acid methyl ester
(Synonyms: r-亚麻酸甲酯,Methyl GLA,Methyl γ-Linolenate) 目录号 : GC10020
A dietary ω-6 PUFA
Cas No.:16326-32-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
γ-Linolenic Acid methyl ester is a weak leukotriene B4 (LTB4) receptor antagonist.
LTB 4, a potent neutrophil chemoattractant, is present at high concentrations in psoriatic lesions, bronchoalveolar lavage in asthmatics and rectal dialysates in patients with inflammatory bowel disease.
In vitro: γ-Linolenic acid methyl ester is an esterified version of the free acid which is less water soluble but more amenable for the formulation of GLA-containing diets and dietary supplements. GLA was identified as an ω-6 fatty acid which could be elongated to arachidonic acid for endogenous eicosanoid synthesis. GLA was found to be a weak leukotriene B4 (LTB4) receptor antagonist, which was able to inhibit [3H]-LTB4 binding to porcine neutrophil membranes with a Ki of 1 μM [1].
In vivo: In an in-vivo model of LTB4-induced bronchoconstriction, ricinelaidic acid andγ-Linolenic acid methyl ester at a 1 mg/kg i.v. dose could result in 46% and 53% inhibition, respectively, indicating that essential fatty acids are LTB4 receptor antagonists, which may account in part for their reported anti-inflammatory activities [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Yagaloff, K. A.,Franco, L.,Simko, B., et al. Essential fatty acids are antagonists of the leukotriene B4 receptor. Prostaglandins, Leukotrienes and Essential Fatty Acids 52, 293-297 (1995).
| Cas No. | 16326-32-2 | SDF | |
| 别名 | r-亚麻酸甲酯,Methyl GLA,Methyl γ-Linolenate | ||
| 化学名 | 6Z,9Z,12Z-octadecatrienoic acid, methyl ester | ||
| Canonical SMILES | CCCCC/C=C\C/C=C\C/C=C\CCCCC(OC)=O | ||
| 分子式 | C19H32O2 | 分子量 | 292.5 |
| 溶解度 | ≤100mg/ml in DMSO;100mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4188 mL | 17.094 mL | 34.188 mL |
| 5 mM | 0.6838 mL | 3.4188 mL | 6.8376 mL |
| 10 mM | 0.3419 mL | 1.7094 mL | 3.4188 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet